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A B S T R A C T
Background: Phenanthrenes isolated from Juncus species possess diﬀerent biological activities, including anti-
proliferative and antimigratory eﬀects.
Purpose: In this study, nine phenanthrenes isolated from the roots of Juncus inﬂexus were investigated for their
antiproliferative activity on several gynecological cancer cell lines, using non-cancerous cells as controls.
Methods: Antiproliferative activities of the compounds were determined by means of MTT assay. Flow cytometry
was used for cell cycle analysis and determination of mitotic cells. Activities of caspase-3, -8, and -9 were
detected by colorimetric kits. Tubulin polymerization was followed by kinetic absorbance determination. Action
on tumor cell migration was described using wound healing assay. Western blot assays were used to determine
apoptosis-related factors at protein level.
Results: Among the compounds tested, juncusol exhibited the most substantial antiproliferative eﬀect against
cervical cancer HeLa cells. It was also revealed that juncusol has a distinct growth inhibitory eﬀect in cervical
cancer cell lines of various HPV status: it was highly active in HPV type 18-positive HeLa cells, while it was
inactive in HPV type 16-positive SiHa and CaSki cells. Cell cycle analysis showed an increase in G2/M and subG1
cell populations after juncusol treatment. Caspase-3, -8, and -9 were detected to be activated by juncusol in HeLa
cells, indicating that juncusol induces apoptotic cell death. Moreover, juncusol inhibited tubulin polymerization,
as well as EGFR activation, suggesting two possible additional mechanisms that may account for juncusol's
inducing a G2/M-phase cell cycle arrest and inhibiting cell migration.
Conclusion: These results suggest that juncusol is a potent antiproliferative agent against HPV-18 related cervical
cancer and may be considered as a lead compound for the development of innovative anticancer agents.
Introduction
Global cancer burden continues to increase, thus improving cancer
treatment approaches is an important medical need (Jemal et al.,
2011). Abnormally growing cells with inﬁnite replication due to cell
cycle disorders may escape apoptosis, resulting in the development of
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tumors. Since these cells are able to migrate throughout the body and
invade distant organ sites, the cancerous process may easily become
generalized. Both conventional chemotherapy and current gene-tar-
geted therapies restrain cell cycle progression, inducing cell death and
control metastasis (Deep and Agarwal, 2008; Ricci and Zong, 2006;
Steeg, 2016). Currently these are the major and most eﬀective ap-
proaches for cancer treatment. However, the greatest challenge of
currently available chemotherapeutic agents is the lack of selectivity,
resulting in serious side eﬀects that often limit their treatment spectrum
(Hannun, 1997). Thus, research for chemotherapeutical agents with
unique mechanisms of action assuring high selectivity has been in the
focus of cancer research for decades.
Microtubules play an essential role in cellular processes, such as cell
division, migration, intracellular transport, structural integrity, and
adaptation to a variety of conditions to interact with the environment
(Akhshi et al., 2014; Komlodi-Pasztor et al., 2011). Based on treatment
success rates of more selective drugs developed so far, microtubules are
still considered as one of the best cancer targets (Chan et al., 2012;
Jordan and Wilson, 2004). Microtubule-targeted antimitotic agents
(MTAs) in clinical use or under clinical development are classiﬁed into
two main groups. Microtubule-stabilizing agents belong to group one,
and include agents such as paclitaxel, docetaxel, the epothilones and
discodermolide, which all stimulate microtubule polymerization. The
other group includes microtubule-destabilizing agents, which inhibit
microtubule polymerization, such as Vinca alkaloids, halichondrins,
cryptophycins, combretastatins, estramustine and colchicine
(Jordan, 2002). Originally, several of the MTAs were extracted from
plants, e.g. paclitaxel, Vinca alkaloids, and colchicines were ﬁrst iso-
lated from the stem bark of Taxus brevifolia (western yew), Catharanthus
roseus (L.) G. Don. (periwinkle) leaves and Colchicum autumnale (au-
tumn crocus), respectively (Moudi et al., 2013; Popovic et al., 1981;
Wani et al., 1971). Herbs and their extracts as natural sources of
bioactive molecules with diverse and original chemical structures are
critically important resources for drug discovery and development,
even though usually they are not the ﬁnal drug entities that may enter
into therapy (Newman and Cragg, 2012; Newman et al., 2003).
Phenanthrenes are rare aromatic secondary plant metabolites,
which have been isolated from plants belonging to diﬀerent families
(e.g. Combretaceae, Dioscoreaceae, Juncaceae, and Orchidaceae). Their
promising biological properties, including cytotoxic, antioxidant, anti-
viral, antimicrobial and anti-inﬂammatory activities, have generated
signiﬁcant research interest on phenanthrenes worldwide (Kovács
et al., 2008; Tóth et al., 2018). Juncaceae species are abundant sources
of phenanthrenes. Up to now, more than one hundred phenanthrenes
were isolated from diﬀerent Juncus and Luzula species (Bús et al.,
2018). Plants belonging to these two genera are cosmopolitans but most
of them occur in the northern hemisphere (Williams and Harborne,
1975). Phenanthrenes are the main bioactive components of Juncus
species, and some of them have been demonstrated to exhibit potent
cytotoxic activity in vitro (Ishiuchi et al., 2015; Ma et al., 2015; Miles
et al., 1977; Su et al., 2013; Tóth et al., 2016a). However, the anti-
proliferative properties and the mechanisms of action of the isolated
phenanthrenes have not yet been exhaustively studied. Therefore, in
our study nine phenanthrenes (juncuenin A, dehydrojuncuenin A, jun-
cuenin B, dehydrojuncuenin B, juncusol, dehydrojuncusol, and jin-
ﬂexins A–C), isolated previously from the roots of Juncus inﬂexus were
investigated for their selective cytotoxicity, including their eﬀects on
microtubule dynamism, cell cycle progression, and apoptosis in cancer
cell lines. J. inﬂexus L. is a perennial plant, native to the Carpathian
Basin and occurs in fens, wet grasslands and damps (Tóth et al., 2016;
Snogerup, 1980).
Our aim was to examine the chemotherapeutic potential of these
phenanthrenes, as well as to determine their possible mechanisms of
action to open up new opportunities for the design and development of
original antitumor agents.
Materials and methods
Cell culturing
HeLa, A2780, and T47D cell lines (isolated from cervical, ovarian
and breast carcinomas, respectively) were purchased from the
European Collection of Cell Cultures (ECACC, Salisbury, UK). Human
breast cancer cells MDA-MB-231 were purchased from the Culture
Collection and Research Centre (CCRC) of the Food Industry Research
and Development Institute (FIRDI, Hsinchu, Taiwan). Two HPV-posi-
tive cervical carcinoma cell lines, SiHa and CaSki, were obtained from
the American Type Culture Collection (Rockville, MD). The human skin
ﬁbroblast cell line CCD966SK was obtained from the Bioresource
Collection and Research Center (BCRC, Hsinchu, Taiwan). All cells were
maintained in Dulbecco's modiﬁed Eagle's medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10% fetal bovine serum (Thermo
Fisher Scientiﬁc, Waltham, MA, USA) and were cultured at 37 °C in a
humidiﬁed 5% CO2 incubator (NuAire, Plymouth, MN, USA).
Chemicals and treatment
Phenanthrenes were isolated from the roots of J. inﬂexus (purity of
the compounds >95%) (Tóth et al., 2016a,b). The cytostatic drugs
nocodazole (Jordan et al., 1992) and wortmannin (Wang et al., 2015)
employed as positive controls and all other substances, if otherwise not
speciﬁed, were purchased from Sigma-Aldrich. All chemicals were
dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions.
Determining the antiproliferative activities of the test compounds
A stock solution of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) was prepared in phosphate buﬀer saline (PBS) at
a concentration of 5mg/ml. 5× 103 cells per well were seeded in
100 μl medium on 96-well plates and incubated for cell adhesion for
24 h. After 72 h of treatment with increasing concentrations of phe-
nanthrene compounds (0.1–30.0 μM), the cell growth medium was re-
placed with complete fresh medium containing MTT at a ﬁnal con-
centration of 0.5 mg/ml and incubated for 4 h. The medium was
removed from the wells, and 100 μl of DMSO was added to each well in
order to dissolve the formazan crystals. Absorbance at 545 nm was
measured using a STAT FAX 2100 Microplate Reader (Awareness
Technology, Palm City, FL, USA). Sigmoidal dose-response curves were
ﬁtted to the data in order to determine the IC50 values using the
GraphPad Prism 4.0 Software (GraphPad Software; San Diego, CA,
USA).
Antibodies and western blot analyses
Protein extraction and western blot assays were performed as pre-
viously described (Wang et al., 2012). The proteins from collected cells
were extracted with a lysis buﬀer (10 mM Tris, pH 7.5, 1 mM EDTA,
420 mM NaCl, 10% glycerol, and 0.5% NP-40) supplemented with
1mM DTT and a mixture of protease and phosphatase inhibitors (Roche
Applied Science). After executing separation by the SDS-PAGE method
and transfer to nitrocellulose membranes, the proteins were recognized
by primary antibodies followed by horseradish peroxidase-coupled
secondary antibodies (Jackson Immuno Research Laboratories Inc.) and
were detected by the Enhanced chemiluminescence (ECL) reagent
(Millipore). Images were taken using a Luminescent Image Analyzer
System (LAS 4000 mini; Fujiﬁlm). The primary antibodies against
cleaved caspase-3, procaspase-8 and -9, EGFR, EGFR-Y1068 and actin
were purchased from Cell Signaling Technology (Danvers, USA); PARP
was purchased from Santa Cruz Biotechnology Inc. (Dallas, USA).
GAPDH was purchased from Genetex Inc. (Irvine, USA). The expression
of actin served as an internal control.
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Flow cytometry
Propidium iodide-based cell cycle analysis
HeLa cells (300,000–400,000 cells/well) were seeded in 6-well
plates, and cultured overnight, then treated with the indicated con-
centration of juncusol for 24 h. These pretreated cells were washed with
cold 1×PBS, harvested with trypsin and centrifuged at 1900 rpm for
10min. After being washed with 1×PBS and a second round of cen-
trifugation, cells were ﬁxed overnight using ethanol at a ﬁnal con-
centration of 70%. Next, samples were centrifuged to remove ethanol,
and were stained with a propidium iodide (PI) solution containing
0.1 mg/ml PI, 0.02mg/ml RNase A, 0.003ml/ml Triton-X and 1.0 mg/
ml sodium citrate in distilled water. For staining, samples were pro-
tected from light for 1 h at room temperature. The samples were then
analyzed by a PartecCyFlow instrument (Partec GmbH, Munster,
Germany). In each analysis, 20,000 cells were detected and the per-
centage of cells in diﬀerent cell-cycle phases (subG1, G1, S, and G2/M)
were calculated by using the ModFit LT Software (Verity Software
House, Topsham, ME, USA). The sub-diploid subG1 fraction was re-
garded as the apoptotic cell population.
Detection of mitotic cells
Mitosis was detected based on phosphorylation of the serine-10
residue of the N-terminal tail of histone H3, which is highly phos-
phorylated by H3 kinases in the condensed chromosome and is con-
sidered to be a marker of mitosis (Hans and Dimitrov, 2001). HeLa cells
were collected and ﬁxed as described above, washed with 1×PBS, and
then centrifuged for 5 min. After removal of the supernatant, cells were
resuspended in a phospho-Histone H3 (Ser10) antibody solution (Alexa
Fluor® 488 Conjugate) and the sample was incubated for 1 h in dark.
The cells were then washed with 1× PBS and incubated with a sec-
ondary antibody for 1 h. Next, cells were washed with 1×PBS and
centrifuged, then incubated with freshly-prepared propidium iodide/
RNase solution for 30 min, protected from light. Samples were analyzed
on an LSR II Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA). A total of 1× 104 cells were detected. The percentage of cells in
the mitotic phase was determined using the FlowJo software (FlowJo
LLC, Ashland, OR, USA).
Determining caspase activity
Caspase-3, -8, and -9 are apoptosis-related cysteine peptidases.
Caspase-3, -8 and -9 colorimetric enzyme activity assays were per-
formed in order to assess the pro-apoptotic eﬀect of the compounds
tested. 1× 107 HeLa cells were seeded and incubated overnight at
37 °C, then were treated with 3 or 10 μM of juncusol for 24 h. The cells
were counted and washed in 1×PBS. Centrifuged samples were sus-
pended in 100 μl of chilled cell lysis buﬀer and kept on ice for 20 min.
The lysate was centrifuged, and the supernatant (cytosolic extract) was
collected. Protein concentration in the lysate was determined by the
Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA).
Samples were diluted so as to have 100 μg protein in 50 μl cell lysis
buﬀer. According to the manufacturer's protocol, 10 μl of treated and
untreated cell lysates, respectively, were incubated with 10 μl of se-
lective caspase-3 substrate (N-acetyl-Asp-Glu-Val-Asp p-nitroanilide), or
caspase-8 substrate (N-acetyl-Ile-Glu-Thr-Asp p-nitroanilide) in a ﬁnal
volume of 100 μl assay buﬀer. 50 μl portions of treated and untreated
cell lysates were incubated with 5.0 μl of selective caspase-9 substrate
(N-acetyl-Leu-Glu-His-Asp p-nitroanilide) in a ﬁnal volume of 105 μl
reaction buﬀer containing 10mM dithiothreitol. After an overnight
incubation at 37 °C, absorbance of the released p-nitroaniline was
measured at 405 nm with a microtiter plate reader.
Tubulin polymerization assay
A tubulin polymerization assay kit (Cytoskeleton Inc., Denver, CO,
USA) was used according to the manufacturer's instructions in order to
characterize cell-independent direct eﬀects of juncusol on tubulin
polymerization in vitro. 10 μl of 200 μM juncusol solution was added to
a prewarmed (37 °C) UV-transparent microplate. 10 μl samples of
10 μM paclitaxel and general tubulin buﬀer (80mM PIPES pH 6.9,
2 mM MgCl2, 0.5 mM EGTA) were used as positive and untreated con-
trols, respectively. Next, 100 μl of 3.0mg/ml tubulin dissolved in
polymerization buﬀer (80mM PIPES pH 6.9, 2 mM MgCl2, 0.5 mM
EGTA, 1mM GTP, 10.2% glycerol) was added to each sample in sepa-
rate wells of 96 well plates. The plate was immediately placed into an
ultraviolet spectrophotometer (SPECTROstarNano, BMG Labtech,
Ortenberg, Germany), which was prewarmed to 37 °C. A 90min kinetic
reaction was started and the absorbance was determined at 340 nm
every minute. To evaluate the eﬀects of juncusol, the tubulin poly-
merization curve was outlined by plotting the optical density against
time. The maximum reaction rate (Vmax; Δabsorbance/min) was cal-
culated based on the highest diﬀerence in the absorbance of ﬁve con-
tinuous time points of the kinetic curve.
Cell migration assay
A speciﬁc wound assay chamber (ibidi GmbH, Martinsried,
Germany) kept in a cell-free space of 400 μm in width between two-well
culture rooms. HeLa cells (3× 104 cells per well) were seeded in each
well of the culture-insert. After 24 h, the chambers were removed and
washed with 1× PBS in order to extract non-adherent cells and cellular
debris. Cells were treated with indicated concentrations of the com-
pounds for 24 h. Images were obtained before and 24 h after juncusol
treatment, using a digital CCD camera mounted on an inverted micro-
scope (Axiovert 40, Zeiss, Thornwood, NY, USA). Wound distances
were calculated using the AxioVision Release 4.8 software (Carl Zeiss
AG, Oberkochen, Germany).
Data statistics
Data statistics were calculated from three independent experiments.
For the statistical analysis of our experimental data, GraphPad Prism
version 5.0 was used (GraphPad Software, San Diego, CA, USA).
Diﬀerences between pre- and post-treatment values or between jun-
cusol-treated and control samples were evaluated using one-way
ANOVA with Newman–Keuls post-test. All data are expressed as
mean ± standard error of the mean (SEM). For the graphical pre-
sentation of our results, statistical signiﬁcance is indicated with an as-
terisk for p values <0.05, two asterisks for p<0.01, and three asterisks
for p<0.001.
Results
Phenanthrenes exhibit antiproliferative activity in adherent human cancer
cells
Nine phenanthrenes (juncuenin A, dehydrojuncuenin A, juncuenin
B, dehydrojuncuenin B, juncusol, dehydrojuncusol, jinﬂexin A, jinﬂexin
B, and jinﬂexin C), isolated previously from the roots of J. inﬂexus
(Tóth et al., 2016a), were investigated for their antiproliferative ac-
tivities (Fig. 1). Breast cancer (MDA-MB-231 and T47D), ovarian cancer
(A2780) and cervical cancer (HeLa) cells were treated with each phe-
nanthrene (0.1–30 μM) for 72 h, and the antiproliferative activity of
each compound was determined by the MTT assay in vitro. Juncuenin B,
dehydrojuncusol, juncusol, jinﬂexin A, and dehydrojuncuenin B exerted
a substantially greater antiproliferative eﬀect on HeLa cells than on
other cell types (Table 1). HeLa was detected to be the most sensitive
cell line while T47D cells proved to be resistant to all tested phenan-
threnes.
Some conclusions on the structure-activity relationship can be
drawn from our data regarding the antiproliferative activities of the
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compounds found to be active against certain tumor cell lines. Since
dehydrojuncuenin A, juncuenin A and jinﬂexin C did not exhibit any
relevant actions (i.e. their calculated IC50 values were above 30 μM), it
seems that the combined presence of methyl, hydroxy and vinyl sub-
stituents on ring C are required for the antiproliferative eﬀect.
Regarding that jinﬂexin B was found to be ineﬀective, it indicates that a
methyl and a hydroxy group is preferred on ring A. Concerning the
saturation state of the compounds (juncusol vs. dehydrojuncusol, and
juncuenin B vs. dehydrojuncuenin B) the double bond between C-9 and
C-10 seems to decrease potency.
Among the tested phenanthrenes, juncusol was characterized with
the lowest IC50 value (0.95 μM) in HeLa cells. Thus, juncusol was
chosen for our further investigations to evaluate its safety in a normal
cell line. We have demonstrated that juncusol has no toxic eﬀects on
normal human skin ﬁbroblasts (CCD966sk) at even the highest con-
centration tested (30 µM). As juncusol proved to exhibit a signiﬁcant
antiproliferative eﬀect against HeLa cells with a high therapeutic index,
in the next step the molecular mechanisms of its action in HeLa cells
were investigated.
Juncusol exerts no substantial activity against other cervical cancer cell lines
More than 90% of cervical cancers are associated with human
papillomavirus (HPV) infection (Walboomers et al., 1999). Besides
HeLa cells containing integrated copies of HPV type 18 DNA, CaSki and
SiHa cervical cancer cell lines containing HPV type 16 DNA were also
treated with juncusol to test its eﬃcacy. Results have shown that jun-
cusol has a substantial growth inhibitory eﬀect on HeLa cells, but not on
CaSki and SiHa cells even when those are exposed to a high con-
centration (30 µM) of the test compound for 72 h (Fig. 2).
Juncusol arrests cell cycle progression at the G2/M phase
Regulators of cell cycle progression that interfere with protein sig-
nals are interrelated with multiple cellular processes, including cell
proliferation, apoptosis, cell migration and DNA repair. We analyzed
the eﬀects of juncusol on cell cycle progression after 24 h and 48 h of
exposure to identify the possible protein signals aﬀected by juncusol in
HeLa cells. After 24 h of juncusol exposure we have detected an in-
crease in the number of cells in the G2/M and subG1 cell cycle phases,
accompanied by a decrease in the number of cells in the S phase
(Fig. 3A). Applying a lower concentration (1 µM) of juncusol for an
extended period of time i.e. for 48 h, proved to induce a cell cycle
distribution similar to that produced by treatment with 3 µM juncusol
for 24 h. Treatment with 3 µM juncusol for 48 h resulted in a marked
increase in the G2/M phase and a decrease in the G1 phase population
Fig. 1. Chemical structures of the nine phenanthrenes examined.
Table 1
Antiproliferative activity of the nine phenanthrenes tested in cancer cells and normal skin ﬁbroblasts.
Compound Cancer cell lines Fibroblasts
MDA-MB-231 T47D HeLa A2780 CCD966SK
Juncuenin A >30 >30 >30 >30 ND
Dehydrojuncuenin A >30 >30 >30 >30 ND
Juncuenin B 9.41 ± 1.88 >30 2.91 ± 0.46 7.31 ± 1.27 ND
Dehydrojuncuenin B 13.30 ± 4.11 >30 16.57 ± 1.53 7.87 ± 1.07 ND
Juncusol >30 >30 0.95 ± 0.01 13.83 ± 1.31 >30
Dehydrojuncusol >30 >30 2.22 ± 0.14 15.76 ± 0.89 ND
Jinﬂexin A >30 >30 17.38 ± 0.38 >30 ND
Jinﬂexin B >30 >30 >30 >30 ND
Jinﬂexin C >30 >30 >30 >30 ND
IC50 values (µM, mean ± SEM) were determined in an MTT assay by treating the cells with each compound (0.1–30 μM) for 72 h. Data are based on three
independent experiments and represent means. (ND: not determined).
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(Fig. 3B). These results indicate that juncusol causes a cell cycle
blockade at the G2/M phase with subsequent apoptosis.
Juncusol's proapoptotic eﬀects are mediated by caspase-dependent pathways
The increase in the subG1 cell population suggests that juncusol
may induce cell apoptosis. Caspase enzymes play a key role in apoptotic
cell death, and are classiﬁed by their proapoptotic functions. Caspase-3
catalyzes speciﬁc cleavage of many vital cellular proteins, and it is
activated by caspase-8 and caspase-9 via the death ligand-mediated
extrinsic and mitochondria-mediated intrinsic pathways, respectively
(Porter and Janicke, 1999). To clarify the involvement of intrinsic and
extrinsic apoptotic pathways in juncusol-induced cell death, we tested
for the activities of caspase-3, caspase-8, and caspase-9 in HeLa cells
pretreated with 3 and 10 μM juncusol for 24 h (Fig. 4A). Our results
showed that juncusol causes a signiﬁcant and concentration-dependent
increase in caspase-3 activity compared to untreated cells. Moreover,
caspase-8 and -9 enzymes also exhibited increased activities after ex-
posure to the same treatment conditions indicating that juncusol in-
duces both the intrinsic and extrinsic apoptotic pathways. It was further
conﬁrmed by a Western blot assay, which supported that juncusol in-
creased the activity of caspases, as indicated by an increased level of the
cleaved form of caspase-3 as well as of caspase-3 substrate PARP.
Cleavage intensity of 10 μM juncusol is comparable to that of 80 nM
paclitaxel (Fig. 4B). The same juncusol treatments decreased the
amount of procaspase-8 and -9. These results suggest that juncusol-in-
duced cell death is mediated via a caspase-dependent pathway.
Eﬀects of juncusol on tubulin polymerization in vitro
Tubulin polymerization plays a signiﬁcant role in balancing the
polymerization and degradation of microtubules from tubulin dimers
during mitosis. To identify the mechanisms behind the G2/M phase cell
cycle blockade induced by juncusol, tubulin polymerization activity
was evaluated using an in vitro cell-free system. The kinetic curves for
tubulin polymerization are shown in Fig. 5A. Our reference agent pa-
clitaxel, a standard microtubule-disturbing compound used in clinical
practice, was detected to increase polymerization rate at a concentra-
tion of 10 μM, indicating a marked action on tubulin dynamics. Jun-
cusol, on the other hand, was found to decrease tubulin polymerization
rate at a concentration of 200 μM. The calculated Vmax value for pa-
clitaxel is 0.071, which is signiﬁcantly higher than that of the blank
control (Vmax = 0.017), while Vmax for juncusol is 0.008 which is
Fig. 2. Eﬀects of juncusol on proliferation in human cervical cancer cell
lines in vitro. Cell viability was evaluated for CaSki, SiHa, and HeLa cells after
treatment with increasing concentrations of juncusol (0.1–30 µM) in an MTT
assay for 72 h. Results are based on three independent experiments, and are
expressed as means with standard error bars, n=5.
Fig. 3. Eﬀects of juncusol on cell cycleprogression. HeLa cells were treated with the indicated concentrations of juncusol for 24 h (A) or 48 h (B). * p< 0.05, **
p< 0.01 and *** p< 0.001 compared to untreated control in the same cell cycle phase. Results are mean values ± SEM from three measurements.
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signiﬁcantly lower than that of the blank control (Fig. 5B).
Eﬀects of juncusol on mitosis
Histones are DNA-binding proteins that control condensation and
ordered DNA package during mitosis, mainly regulated by post-trans-
lational modiﬁcations. Phosphorylation at a highly conserved serine 10
residue of the N-terminal tail of histone H3 occurs upon the initiation of
mitosis (Prigent and Dimitrov, 2003). Since juncusol signiﬁcantly in-
creased the number of cells at the G2/M phase (Fig. 3), we analyzed the
DNA content in parallel with histone H3 phosphorylation in order to
clarify if juncusol aﬀects mitosis. Results showed that our control agent
nocodazole, a chemical well-known to block microtubule polymeriza-
tion (Jordan et al., 1992) signiﬁcantly increases the percentage of cells
with phosphorylated histone H3, while juncusol treatment did not alter
the proportion of cells expressing serine 10 phosphorylated histone H3
(Fig. 6).
Eﬀects of juncusol on EGFR activation
Based on our ﬁndings that juncusol had no inﬂuence on the number
of cells in the M phase but increased the proportion of G2/M cells, we
presumed that juncusol should cause a cell cycle arrest of HeLa cells in
the G2 phase. It is known that epidermal growth factor receptor (EGFR)
is required for the G2 to M phase transition during the cell cycle
(Baker and Yu, 2001) and it is a key regulator that controls multiple cell
functions including cell survival, proliferation, angiogenesis, and me-
tastasis (Normanno et al., 2006). In order to understand the mechanism
of the hypothesized G2 to M phase transition arrest induced by jun-
cusol, we examined EGFR activation as detected by EGFR autopho-
sphorylation (Fig. 7A). In serum-starved HeLa cells EGFR stimulation
by epidermal growth factor markedly increased EGFR phosphorylation
at the tyrosine 1068 residue which could be suppressed by the EGFR
inhibitor AG1478 or juncusol. As clinical studies revealed that recurrent
and metastatic tumors have higher levels of EGFR-1 expression
(Bellone et al., 2007), juncusol may inhibit metastasis formation by
reducing EGFR activation as indicated by our experiments. Thus, we
further aimed to conﬁrm the relationship between reducing EGFR ac-
tivation and metastasis inhibition, so we investigated the eﬀects of
juncusol on EGF-induced cell migration using the wound healing assay
under serum-free conditions (Fig. 7B and C). EGF treatment enhanced
cell migration across wound borders and resulted in almost 50% wound
closure after EGFR stimulation for 24 h, whereas simultaneous treat-
ment with 1–10 μM of juncusol or 1 μM of wortmannin resulted in
wider wound border distances compared to EGF treatment. These re-
sults suggest that juncusol inhibits EGF-induced cell migration in HeLa
cells by EGFR inhibition, or probably by proteins that are associated
with its signaling, such as PI3K.
Discussion
Approximately two-thirds of anticancer drugs are of natural origin,
including synthetic drugs with a natural basis called nature-inspired
drugs (Newman and Cragg, 2012). The antiproliferative activities of
nine phenanthrenes, isolated previously from J. inﬂexus were in-
vestigated against four human cancer cell lines. The mechanism of
Fig. 4. Characterization of apoptotic cell death induced by juncusol.
Caspase activities were determined after 24 h of treatment with the indicated
concentrations of juncusol and without it as control. Results represent the fold
increase of enzyme activity in juncusol-treated cells compared to untreated
controls. Data are means ± SEM, n=3. ⁎⁎p<0.01, ⁎⁎⁎p< 0.001 compared to
untreated control. ♯♯♯p< 0.001 compared to cells treated with 3 μM juncusol
(A). Cells were treated with the indicated concentrations of juncusol or pacli-
taxel for 24 hbefore performing a Western blot assay to detect cleaved caspase-3
and PARP (B).
Fig. 5. Eﬀects of juncusol on cell-free tubulin polymerization. Kinetic
curves demonstrating the eﬀects of 200 μM juncusol and 10 μM paclitaxel on
tubulin polymerization in 60 min (A). Maximum rate of tubulin polymerization
determined from the in vitro kinetic assay. Results are based on two in-
dependent measurements, and are expressed as mean ± SEM, n=4.
*p<0.05, ⁎⁎⁎p< 0.001 compared to untreated control (B).
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action and cancer selectivity of the most eﬀective compound, juncusol
was additionally investigated on the most sensitive cell line used. We
have successfully demonstrated two mechanisms that may contribute to
juncusol's eﬀect on delaying cancer progression. First, inhibition of
EGFR activation was demonstrated as juncusol was shown to inhibit
EGF-induced EGFR autophosphorylation as well as cell migration
(Fig. 7). EGFR initiated DNA synthesis, enhanced cell growth, invasion
and metastasis are proved to support cancer progression
(Normanno et al., 2006). Based on the results of cell-cycle analysis, we
assumed that juncusol may aﬀect cell cycle transition from G2 to M
phase, resulting in a G2/M arrest. If juncusol induces cell cycle arrest
only at the G2 phase, those cells which are already in mitosis before
treatment should reach the G1 phase soon after adding juncusol to the
cell culture. However, juncusol did not change the proportion of M
Fig. 6. Eﬀects of juncusol on mitosis in HeLa cells. After treatment with 3–30 μM of juncusol or 50 nM of nocodazole for 24 h, the cells were stained with PI and
ﬂuorescent anti-phospho-histone H3 serine-10 antibody, and were analyzed by ﬂow cytometry. Mitotic cells were gated and counted (A). The percentages of mitotic
cells are calculated from three independent experiments, and are expressed as mean ± SEM (A). ⁎⁎⁎p< 0.001 compared to DMSO-treated control.
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phase cells, nor that of G1 cells (Fig. 6), suggesting that another me-
chanism might be responsible for the observed cell cycle arrest. Indeed,
juncusol was detected to display a MTA-like characteristic by inhibiting
tubulin polymerization. Compared to nocodazole that arrests cell cycle
at the M phase, juncusol prevents only the progression of cells that are
already in the M phase, i.e. it aﬀects only those cells that have already
been in the mitotic phase before treatment. Juncusol causes a G2/M
arrest by limiting G2- and M-phase progression which is a frequent
character of chemically related phenolic natural products including
chalcones and ﬂavonoids (Wang et al., 2018; Zhang et al., 2018).
Taxanes and Vinca alkaloids that are widely used in cancer che-
motherapy belong to the MTA family which disrupts microtubule and
tubulin dynamics. Such agents perturb mitotic functions and micro-
tubule-dependent traﬃcking and interaction with actin (Akhshi et al.,
2014; Komlodi-Pasztor et al., 2011). Based on our results, it is reason-
ably assumed that juncusol may possess a novel mechanism of action
besides the well-known MTA mechanisms. The impact of juncusol on
cell cycle distribution is similar to that of the phenanthrene derivative
PJ-34 and the phenanthrene quinone tanshinone I. These compounds
have chemical structures similar to that of juncusol, and are considered
to exert diﬀerent eﬀects, especially on cell death. Both PJ-34 and tan-
shinone I are known to induce apoptosis by activating a mitochondrial-
mediated intrinsic pathway in various cell types (Bai et al., 2015;
Gangopadhyay et al., 2014; Liu et al., 2010; Su et al., 2008). Juncusol
concentration-dependently increased the activity of caspase-3, -8, and
-9 indicating it induces both the intrinsic and extrinsic apoptotic
pathways. Besides, increase of the cleaved forms of caspase-3 and
PARP, and the elevated ratio of the sub-G1 cell population also conﬁrms
that juncusol treatment induces apoptosis. PJ-34 was reported to inhibit
the extra-centrosome clustering of MDA-MB-231 cells resulting in G2/
M phase arrest and cell death probably via a mitotic catastrophe
(Castiel et al., 2011). Regarding that tubulin is an essential module of
the centrosome clustering process (Ogden et al., 2012), as well as of
centrosome maturation (Winey, 1999), disturbed tubulin polymeriza-
tion results in decluttering and centrosome immaturity which might
also play a role in the overall action of juncusol on cell cycle.
Due to the oncogenic properties mediated by EGFR in diﬀerent
malignant processes, EGFR-targeting drugs are commonly used in
clinical cancer therapy. Numerous anti-EGFR monoclonal antibodies
(e.g. cetuximab, panitumumab) recognize and block the extracellular
domain of the EGF receptor protein, while other small molecules (e.g.
geﬁtinib, erlotinib, lapatinib, canertinib) inhibit the intracellular kinase
domain. Both types of EGFR inhibitors have substantial beneﬁts in
terms of increasing survival rates of patients when therapy is combined
with chemotherapeutic or chemopreventive agents (Bareschino et al.,
2007; Petrelli et al., 2011; Rocha-Lima et al., 2007). We suggest that
juncusol, combined with chemotherapeutic agents, could also have the
beneﬁt to increase the success rates in oncotherapy based on its EGFR
inhibiting activity. Numerous molecular mechanisms are linked to cell
migration, including the EGFR/PI3K/AKT or EGFR/STATs/JAKs sig-
naling axes (Andl et al., 2004; Zhou et al., 2006). These have been
further conﬁrmed by our study. Both wortmannin and juncusol sig-
niﬁcantly inhibited HeLa cell migration via inhibiting PI3K, and a direct
or indirect inhibition of EGFR, respectively (Fig. 7). As demonstrated in
the wound healing assay, juncusol inhibited cell migration after 24 h
incubation at a concentration that approximates the IC50 value at 72 h.
Therefore, we consider that juncusol is more likely to inhibit EGF-
mediated migration than to induce cell death. However, only 3–30 μM
juncusol could inhibit the marked EGFR phosphorylation induced by
elevated EGF levels (Fig. 7A). This concentration is higher than what is
required to inhibit EGF-induced cell migration. We presume that be-
sides EGFR inhibition, additional mechanisms are also involved in the
cell migration inhibitory action of juncusol. It may also act on down-
stream regulators of EGFR, on the cytoskeleton, or on cell adhesion
molecules. Our experiments have clearly demonstrated that juncusol
inhibits tubulin polymerization which should be taken into considera-
tion upon evaluating its eﬀect on cell migration.
Juncusol has demonstrated selective antiproliferative activities on
three cervical cancer cell lines and on normal ﬁbroblasts. It was found
to exert a more pronounced inhibitory eﬀect on HeLa than on CaSki and
SiHa cells (Fig. 2). CaSki is known to be less sensitive to the EGFR-
inhibitor geﬁtinib (Qureshi et al., 2016) which may probably be in
correlation with its higher EGFR expression compared to HeLa and SiHa
cells (Bachran et al., 2010). Regarding the complex eﬀects of juncusol,
EGFR-inhibition cannot solely explain its selectivity towards HPV-18-
positive HeLa cervical cancer cells. It may be explained by the diﬀerent
sensitivity of various HPV-infected cell lines to apoptosis induction.
Restoring p53 function is known to play an important role in the
therapy of HPV-related tumors because the p53 protein is degraded and
inhibited by HPV oncoprotein E6-mediated mechanisms (Thomas et al.,
Fig. 7. Eﬀects of juncusol on EGF sti-
mulation in HeLa cells. Immunoblots
show the eﬀects of juncusol on the activa-
tion of EGFR, based on detecting phos-
phorylated-EGFR antibodies. HeLa cells
were serum-starved for 24 h before EGF
stimulation and were pretreated with the
indicated concentrations of juncusol for
30 min, and then co-treated with 20 nM of
EGF for another 30 min (A).Cells treated
with or without 1–10 μM of juncusol plus
20 nM of EGF. Based on the images taken,
the distance between wound borders were
measured at time 0 and 24 h post-treat-
ment (B).The percentage of wound closure
at 24 h was calculated. Data are based on
three independent experiments and re-
present mean ± SEM (C). ⁎⁎p< 0.005,
⁎⁎⁎p< 0.001 compared to DMSO-treated
control.
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1999). According to previous reports, HeLa cells are more sensitive to
p53-induced apoptosis than SiHa and CaSki cells in a p53-over-
expressing system (Ahn et al., 2002). Thus, our ﬁndings of juncusol's
selectivity towards HPV-18-positive HeLa cells may be explained by
HeLa cells harboring a higher ability to accumulate nuclear p53 upon
the apoptotic insult compared to the other two cell lines, HPV-16-po-
sitive SiHa and CaSki cells (Hietanen et al., 2000). However, it is un-
clear why a p53-responsive eﬀect diﬀers between cervical cancer cells
infected by diﬀerent HPV-types. HPV-type selectivity of juncusol should
be veriﬁed on other cancer cell lines containing DNA of diﬀerent HPV
types.
Conclusion
In the present study, juncusol was screened out in vitro from nine
phenanthrenes and was selectively tested on HeLa cells. Current evi-
dence shows that juncusol inhibits cell-cycle progression, tubulin
polymerization and cell migration. Moreover, it induces apoptosis. We
suggest that juncusol may be regarded as a lead compound for drug
development targeting the treatment of cervical cancer with a speciﬁc
type of HPV infection (HPV-18). This approach has the potential ad-
vantage to selectively target tumor cells and thus minimize side eﬀects.
Conﬂict of interest
The authors declare that they have no conﬂict of interest.
Acknowledgments
This work was supported by research grant 103-2320-B-037-007-
MY3 from the Ministry of Science and Technology (MOST), Taipei,
Taiwan, ROC, as well as by the Hungarian Scientiﬁc Research Fund
(OTKA K-128963 and K-109293) and by GINOP-2.3.2-15-2016-00012
and by Ministry of Human Capacities, Hungary grant 20391-3/2018/
FEKUSTRAT. A bilateral mobility grant of the Hungarian Academy of
Sciences and of the MOST, Taiwan (MOST 106-2911-I-037-504) are
acknowledged. A. Vasas acknowledges the award of a JánosBolyai
scholarship of the Hungarian Academy of Sciences. The authors thank
Dora Bokor, PharmD for proofreading the manuscript.
Supplementary materials
Supplementary material associated with this article can be found, in
the online version, at doi:10.1016/j.phymed.2018.11.030.
References
Ahn, W.S., Han, Y.J., Bae, S.M., Kim, T.H., Rho, M.S., Lee, J.M., Namkoong, S.E., Park,
Y.S., Kim, C.K., Sin, J.I., 2002. Diﬀerential suppression of human cervical cancer cell
growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent
on cell line. Jpn. J. Cancer Res. 93, 1012–1019.
Akhshi, T.K., Wernike, D., Piekny, A., 2014. Microtubules and actin crosstalk in cell
migration and division. Cytoskeleton 71, 1–23.
Andl, C.D., Mizushima, T., Oyama, K., Bowser, M., Nakagawa, H., Rustgi, A.K., 2004.
EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway
in primary esophageal keratinocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 287,
G1227–G1237.
Bachran, D., Schneider, S., Bachran, C., Urban, R., Weng, A., Melzig, M.F., Hoﬀmann, C.,
Kaufmann, A.M., Fuchs, H., 2010. Epidermal growth factor receptor expression af-
fects the eﬃcacy of the combined application of saponin and a targeted toxin on
human cervical carcinoma cells. Int. J. Cancer 127, 1453–1461.
Bai, X.T., Moles, R., Chaib-Mezrag, H., Nicot, C., 2015. Small PARP inhibitor PJ-34 in-
duces cell cycle arrest and apoptosis of adult T-cell leukemia cells. J. Hematol. Oncol.
8, 117.
Baker, N.E., Yu, S.Y., 2001. The EGF receptor deﬁnes domains of cell cycle progression
and survival to regulate cell number in the developing Drosophila eye. Cell 104,
699–708.
Bareschino, M.A., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F., Ciardiello, F.,
2007. Erlotinib in cancer treatment. Ann. Oncol. 18 (Suppl. 6) vi35-41.
Bellone, S., Frera, G., Landolﬁ, G., Romani, C., Bandiera, E., Tognon, G., Roman, J.J.,
Burnett, A.F., Pecorelli, S., Santin, A.D., 2007. Overexpression of epidermal growth
factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-
mediated therapy in recurrent/metastatic disease. Gynecol. Oncol. 106, 513–520.
Bús, C., Tóth, B., Stefkó, D., Hohmann, J., Vasas, A., 2018. Family Juncaceae: promising
source of biologically active natural phenanthrenes. Phytochem. Rev. 17, 833–851.
Castiel, A., Visochek, L., Mittelman, L., Dantzer, F., Izraeli, S., Cohen-Armon, M., 2011. A
phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent
exclusively eradicating human cancer cells. BMC Cancer 11, 412.
Chan, K.S., Koh, C.G., Li, H.Y., 2012. Mitosis-targeted anti-cancer therapies: where they
stand. Cell Death Dis. 3, e411.
Deep, G., Agarwal, R., 2008. New combination therapies with cell-cycle agents. Curr.
Opin. Investig. Drugs 9, 591–604.
Gangopadhyay, N.N., Luketich, J.D., Opest, A., Landreneau, R., Schuchert, M.J., 2014.
PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer
cells. Cancer Invest. 32, 339–348.
Hannun, Y.A., 1997. Apoptosis and the dilemma of cancer chemotherapy. Blood 89,
1845–1853.
Hans, F., Dimitrov, S., 2001. Histone H3 phosphorylation and cell division. Oncogene 20,
3021–3027.
Hietanen, S., Lain, S., Krausz, E., Blattner, C., Lane, D.P., 2000. Activation of p53 in
cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci. USA 97,
8501–8506.
Ishiuchi, K., Kosuge, Y., Hamagami, H., Ozaki, M., Ishige, K., Ito, Y., Kitanaka, S., 2015.
Chemical constituents isolated from Juncus eﬀusus induce cytotoxicity in HT22 cells.
J. Nat. Med. 69, 421–426.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., 2011. Global cancer
statistics. CA Cancer J. Clin. 61, 69–90.
Jordan, M.A., 2002. Mechanism of action of antitumor drugs that interact with micro-
tubules and tubulin. Curr. Med. Chem. Anticancer Agents 2, 1–17.
Jordan, M.A., Thrower, D., Wilson, L., 1992. Eﬀects of vinblastine, podophyllotoxin and
nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in
mitosis. J. Cell Sci. 102 (Pt. 3), 401–416.
Jordan, M.A., Wilson, L., 2004. Microtubules as a target for anticancer drugs. Nat. Rev.
Cancer 4, 253–265.
Komlodi-Pasztor, E., Sackett, D., Wilkerson, J., Fojo, T., 2011. Mitosis is not a key target
of microtubule agents in patient tumors. Nat. Rev. Clin. Oncol. 8, 244–250.
Kovács, A., Vasas, A., Hohmann, J., 2008. Natural phenanthrenes and their biological
activity. Phytochemistry 69, 1084–1110.
Liu, J.J., Liu, W.D., Yang, H.Z., Zhang, Y., Fang, Z.G., Liu, P.Q., Lin, D.J., Xiao, R.Z., Hu,
Y., Wang, C.Z., Li, X.D., He, Y., Huang, R.W., 2010. Inactivation of PI3k/Akt signaling
pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis
in myeloid leukemia cells in vitro. Ann. Hematol. 89, 1089–1097.
Ma, W., Zhang, Y., Ding, Y.Y., Liu, F., Li, N., 2015. Cytotoxic and anti-inﬂammatory
activities of phenanthrenes from the medullae of Juncus eﬀusus L. Arch. Pharm. Res.
39, 154–160.
Miles, D.H., Bhattacharyya, J., Mody, N.V., Atwood, J.L., Black, S., Hedin, P.A., 1977. The
structure of juncusol. A novel cytotoxic dihydrophenanthrene from the Estuarine
marsh plant Juncus roemerianus. J. Am. Chem. Soc. 99, 618–620.
Moudi, M., Go, R., Yien, C.Y., Nazre, M., 2013. Vinca alkaloids. Int. J. Prev. Med. 4,
1231–1235.
Newman, D.J., Cragg, G.M., 2012. Natural products as sources of new drugs over the 30
years from 1981 to 2010. J. Nat. Prod. 75, 311–335.
Newman, D.J., Cragg, G.M., Snader, K.M., 2003. Natural products as sources of new drugs
over the period 1981–2002. J. Nat. Prod. 66, 1022–1037.
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R.,
Carotenuto, A., De Feo, G., Caponigro, F., Salomon, D.S., 2006. Epidermal growth
factor receptor (EGFR) signaling in cancer. Gene 366, 2–16.
Ogden, A., Rida, P.C., Aneja, R., 2012. Let's huddle to prevent a muddle: centrosome
declustering as an attractive anticancer strategy. Cell Death Diﬀer. 19, 1255–1267.
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., Barni, S., 2011. Cetuximab and
panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int. J. Colorectal
Dis. 26, 823–833.
Popovic, M., Gasic, O., Veresbaranji, I., Devetak, Z., 1981. The isolation of colchicoside,
colchicine and oil from Colchicum autumnale seed. Planta Med. 42, 136.
Porter, A.G., Janicke, R.U., 1999. Emerging roles of caspase-3 in apoptosis. Cell Death
Diﬀer. 6, 99–104.
Prigent, C., Dimitrov, S., 2003. Phosphorylation of serine 10 in histone H3, what for? J.
Cell Sci. 116, 3677–3685.
Qureshi, R., Arora, H., Biswas, S., Perwez, A., Naseem, A., Wajid, S., Gandhi, G., Rizvi,
M.A., 2016. Mutation analysis of EGFR and its correlation with the HPV in Indian
cervical cancer patients. Tumour Biol. 37, 9089–9098.
Ricci, M.S., Zong, W.X., 2006. Chemotherapeutic approaches for targeting cell death
pathways. Oncologist 11, 342–357.
Rocha-Lima, C.M., Soares, H.P., Raez, L.E., Singal, R., 2007. EGFR targeting of solid tu-
mors. Cancer Control 14, 295–304.
Snogerup, S., 1980. Juncus L. In: Tutin, T.G., Heywood, V.H., Burges, N.A., Moore, D.M.,
Valentine, D.H., Walters, S.M., Webb, D.A. (Eds.), Flora Europaea Vol. 5.
Alismataceae to Orchidaceae (Monocotyledones). Cambridge University Press,
Cambridge, pp. 102–116.
Steeg, P.S., 2016. Targeting metastasis. Nat. Rev. Cancer 16, 201–218.
Su, C.C., Chen, G.W., Lin, J.G., 2008. Growth inhibition and apoptosis induction by
tanshinone I in human colon cancer Colo 205 cells. Int. J. Mol. Med. 22, 613–618.
Su, X.H., Yuan, Z.P., Li, C.Y., Zhong, Y.J., Du, H.J., Wen, Y.Y., Li, Y.F., Liang, B., 2013.
Phenanthrenes from Juncus eﬀusus. Planta Med 79, 1447–1452.
Thomas, M., Pim, D., Banks, L., 1999. The role of the E6-p53 interaction in the molecular
pathogenesis of HPV. Oncogene 18, 7690–7700.
Tóth, B., Liktor-Busa, E., Kúsz, N., Szappanos, A., Mándi, A., Kurtán, T., Urban, E.,
C.-Y. Kuo, et al. Phytomedicine 58 (2019) 152770
9
Hohmann, J., Chang, F.R., Vasas, A., 2016a. Phenanthrenes from Juncus inﬂexus with
antimicrobial activity against methicillin-resistant Staphylococcus aureus. J. Nat. Prod.
79, 2814–2823.
Tóth, B., Liktor-Busa, E., Urbán, E., Csorba, A., Jakab, G., Hohmann, J., Vasas, A., 2016b.
Antibacterial screening of Juncaceae species native to the Carpathian Basin against
resistant strains and LC-MS investigation of phenanthrenes responsible for the eﬀect.
Fitoterapia 115, 69–73.
Tóth, B., Hohmann, J., Vasas, A., 2018. Phenanthrenes: a promising group of plant sec-
ondary metabolites. J. Nat. Prod. 81, 661–678.
Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V.,
Snijders, P.J., Peto, J., Meijer, C.J., Munoz, N., 1999. Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12–19.
Wang, H.C., Lee, A.Y., Chou, W.C., Wu, C.C., Tseng, C.N., Liu, K.Y., Lin, W.L., Chang, F.R.,
Chuang, D.W., Hunyadi, A., Wu, Y.C., 2012. Inhibition of ATR-dependent signaling
by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-
generating agents in vitro and in vivo. Mol. Cancer Ther. 11, 1443–1453.
Wang, H.C., Chang, F.R., Huang, T.J., Kuo, C.Y., Tsai, Y.C., Wu, C.C., 2015. (-)-Liriopein B
suppresses breast cancer progression via inhibition of multiple kinases. Chem. Res.
Toxicol. 28, 897–906.
Wang, J., Zhang, Y.S., Thakur, K., Hussain, S.S., Zhang, J.G., Xiao, G.R., Wei, Z.J., 2018.
Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via
induction of cell apoptosis and cell cycle arrest. Food Chem. Toxicol. 120, 407–417.
Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P., McPhail, A.T., 1971. Plant antitumor
agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor
agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2327.
Williams, C.A., Harborne, J.B., 1975. Luteolin and daphnetin derivatives in the Juncaceae
and their systematic signiﬁcance. Biochem. Syst. Ecol. 3, 181–190.
Winey, M., 1999. Cell cycle: driving the centrosome cycle. Curr. Biol. 9, R449–R452.
Zhang, Q., Zhang, F., Thakur, K., Wang, J., Wang, H., Hu, F., Zhang, J.G., Wei, Z.J., 2018.
Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry
in HeLa cells. Food Chem. Toxicol. 112, 466–475.
Zhou, C., Qiu, L., Sun, Y., Healey, S., Wanebo, H., Kouttab, N., Di, W., Yan, B., Wan, Y.,
2006. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's eﬀect on
cell death and migration in human ovarian cancer cells. Int. J. Oncol. 29, 269–278.
C.-Y. Kuo, et al. Phytomedicine 58 (2019) 152770
10
